Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico
- PMID: 36633367
- PMCID: PMC10576476
- DOI: 10.1177/00333549221143086
Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico
Abstract
Objective: Treatment for hepatitis C virus (HCV) infection is highly effective; however, people who inject drugs (PWID), the population most affected by HCV, may encounter barriers to treatment. We examined the cascade of care for HCV infection among young adult PWID in northern New Mexico, to help identify gaps and opportunities for HCV treatment intervention.
Methods: Young adults (aged 18-29 y) who self-reported injection drug use in the past 90 days were tested for HCV antibodies (anti-HCV) and HCV RNA. We asked participants with detectable RNA to participate in an HCV education session, prior to a referral to a local health care provider for treatment follow-up, and to return for follow-up HCV testing quarterly for 1 year. We measured the cascade of care milestones ranging from the start of screening to achievement of sustained virologic response (SVR).
Results: Among 238 participants, the median age was 26 years and 133 (55.9%) were men. Most (90.3%) identified as Hispanic. Of 109 RNA-positive participants included in the cascade of care assessment, 84 (77.1%) received their results, 82 (75.2%) participated in the HCV education session, 61 (56.0%) were linked to care through a medical appointment, 27 (24.8%) attended the HCV treatment appointment, 13 (11.9%) attended their follow-up appointment, 6 (5.5%) initiated treatment, 3 (2.8%) completed treatment, and 1 (0.9%) achieved SVR.
Conclusions: We observed a steeply declining level of engagement at each milestone step of the cascade of care after detection of HCV infection, resulting in a suboptimal level of HCV treatment and cure. Programs that can streamline testing and expand access to treatment from trusted health care providers are needed to improve the engagement of PWID in HCV treatment.
Keywords: drug use; hepatitis C treatment.
Conflict of interest statement
Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures

Similar articles
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.Lancet Glob Health. 2023 Dec;11(12):e1885-e1898. doi: 10.1016/S2214-109X(23)00461-8. Lancet Glob Health. 2023. PMID: 37973339
-
A decentralized point of service triple prevention and treatment model for hepatitis B, C and HIV in people who inject drugs in South Africa.Int J Drug Policy. 2025 Sep;143:104894. doi: 10.1016/j.drugpo.2025.104894. Epub 2025 Jun 26. Int J Drug Policy. 2025. PMID: 40578045
-
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis.Lancet Gastroenterol Hepatol. 2025 Apr;10(4):315-331. doi: 10.1016/S2468-1253(24)00442-4. Epub 2025 Feb 21. Lancet Gastroenterol Hepatol. 2025. PMID: 39993400 Free PMC article.
-
Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.J Hepatol. 2024 May;80(5):702-713. doi: 10.1016/j.jhep.2023.12.020. Epub 2024 Jan 17. J Hepatol. 2024. PMID: 38242324 Clinical Trial.
Cited by
-
It may take many villages, but progress can be made toward HCV elimination among people who inject drugs.Lancet Reg Health Am. 2023 May 17;22:100510. doi: 10.1016/j.lana.2023.100510. eCollection 2023 Jun. Lancet Reg Health Am. 2023. PMID: 37388707 Free PMC article. No abstract available.
-
Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.Open Forum Infect Dis. 2025 Apr 8;12(4):ofaf211. doi: 10.1093/ofid/ofaf211. eCollection 2025 Apr. Open Forum Infect Dis. 2025. PMID: 40290563 Free PMC article. Review.
-
Rural-Urban Disparities in Hepatocellular Carcinoma Deaths Are Driven by Hepatitis C-Related Hepatocellular Carcinoma.Am J Gastroenterol. 2025 Apr 11:10.14309/ajg.0000000000003487. doi: 10.14309/ajg.0000000000003487. Online ahead of print. Am J Gastroenterol. 2025. PMID: 40214295
-
Hepatitis C virus care cascade among people who inject drugs in puerto rico: Minimal HCV treatment and substantial barriers to HCV care.Drug Alcohol Depend Rep. 2023 Jul 8;8:100178. doi: 10.1016/j.dadr.2023.100178. eCollection 2023 Sep. Drug Alcohol Depend Rep. 2023. PMID: 37555192 Free PMC article.
-
Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs.J Gen Intern Med. 2023 Nov;38(15):3428-3433. doi: 10.1007/s11606-023-08386-y. Epub 2023 Aug 31. J Gen Intern Med. 2023. PMID: 37653211 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Viral hepatitis surveillance report, 2019. Accessed January 10, 2022. https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous